US Pharma MarketingLantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.
Source: Pharmaceutical Technology